Patent intelligence · US
US 11045461
Compositions of CXCR4 inhibitors and methods of preparation and use
Compositions of CXCR4 inhibitors and methods of preparation and use
Patent details — US 11045461
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 29, 2021
- Expiration
- Jun 24, 2041
- Applicant
- X4 Pharmaceuticals, Inc.
- Claims
- 21
- CPC classes
- A61K, A61K31/47, A61K31/4709, A61K9/485
Quick answer
US 11045461 (Compositions of CXCR4 inhibitors and methods of preparation and use) is held by X4 Pharmaceuticals, Inc.. Status: granted. Granted Jun 29, 2021. Expires Jun 24, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- X4 Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 21
- CPC classes
- A61K, A61K31/47, A61K31/4709, A61K9/485, A61K9/4858, A61K9/4866
More from X4 Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12377090
Methods for treating neutropenia
granted -
US 12285424
Methods for treating neutropenia
granted -
US 12115156
Compositions of CXCR4 inhibitors and methods of preparation and use
granted -
US 11780837
CXCR4 inhibitors and uses thereof
granted -
US 11672793
Compositions of CXCR4 inhibitors and methods of preparation and use
granted -
US 11357742
Methods for treating cancer
granted -
US 11337969
Methods for treating cancer
granted -
US 11332470
CXCR4 inhibitors and uses thereof
granted
Frequently asked questions
What is US patent 11045461?
US 11045461 (Compositions of CXCR4 inhibitors and methods of preparation and use) is held by X4 Pharmaceuticals, Inc.. Status: granted. Granted Jun 29, 2021. Expires Jun 24, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11045461?
X4 Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 16 pharmaceutical patents for this assignee.
When does US 11045461 expire?
Our index shows an expiration date of Jun 24, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.